Trial intelligence / Profile preview

Bemarituzumab + bevacizumab in FGFR2b-overexpressing advanced/metastatic gynecological cancer

2024-516724-33-00Phase 2Completed

Sponsor: Centre Léon Bérard
Start: Jul 2025
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Countries: 1

Overview

Phase 2, single-arm trial of bemarituzumab and bevacizumab in gynecological cancer, sponsored by Centre Léon Bérard. Started Jul 2025; status: completed.

Drugs

bemarituzumabbevacizumab

Conditions

gynecological cancer

Beyond the preview

Go deeper on 2024-516724-33-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2024-516724-33-00.